Gilead Sciencesvs.Incyte
GILD vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 8.0× larger than Incyte by market cap; year to date, Gilead Sciences leads (+19.6% vs +14.9%).
Side by side
| GILD | INCY | |
|---|---|---|
| Market cap | $180B | $22.5B |
| Price | $147.10 | $112.75 |
| Today | +0.2% | −0.6% |
| Return YTD | +19.6% | +14.9% |
| Return 1Y | +25.7% | +30.1% |
| Since June 26, 2026 | +15.0% | −0.9% |
| P/E | — | 14.0 |
| P/S | 5.9 | 3.9 |
| P/B | 15.2 | 3.5 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →More GILD & INCY comparisons
Other head-to-heads in the Biotech & innovation segment.
See where GILD and INCY sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →